Malek Alexandre E, Granwehr Bruno P, Kontoyiannis Dimitrios P
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
IDCases. 2020 Jun 6;21:e00864. doi: 10.1016/j.idcr.2020.e00864. eCollection 2020.
Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.
2019冠状病毒病（COVID-19）是一项重大的公共卫生挑战，目前用于治疗的抗病毒药物储备有限，疗效存疑。人们正在大力努力寻找新的有效药物，但COVID-19新潜在治疗方法的验证可能需要很长时间。因此，需要将现有药物用于新的适应症。在本文中，我们认为将强力霉素与羟氯喹或其他假定药物联合用于COVID-19治疗可能有益，因为强力霉素具有抗病毒和抗炎活性，可减轻细胞因子风暴并预防肺损伤。
